---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-127208"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2024-12-10T23:59:59+00:00"
generated_at: "2026-05-29T05:12:34.150832+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Quoin shareholders approve charter amendments and executive compensation; board grants options

## Summary
- Shareholders approved amendments to Articles reducing quorum to 33 1/3% (25% for foreign private issuers) and aligning special meeting provisions.
- CEO Myers: 2024 base $662,475, FY23 bonus $301,125, option for 536,603 ADSs at $0.78.
- COO Carter: 2024 base $529,980, FY23 bonus $240,900, option for 536,609 ADSs at $0.78.
- CFO Dunn: 2024 base $433,620, FY23 bonus $197,100, option for 338,994 ADSs at $0.78; non-employee directors each received option for 57,014 ADSs at $0.78.

## SEC filing metadata
- accession: 0001104659-24-127208
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2024-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.03, 5.02, 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465924127208/0001104659-24-127208-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465924127208/tm2430603d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-127208
- JSON: https://secwatch.observer/filing/0001104659-24-127208.json
- Plain text: https://secwatch.observer/filing/0001104659-24-127208.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.